This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ultragenyx (RARE) Looks Good: Stock Adds 8.2% in Session
by Zacks Equity Research
Ultragenyx (RARE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
by Zacks Equity Research
Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.
Akero Therapeutics (AKRO) Jumps: Stock Rises 8.9%
by Zacks Equity Research
Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session
by Zacks Equity Research
Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
3 Reasons Why Emergent Biosolutions (EBS) Is a Great Growth Stock
by Zacks Equity Research
Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.
Vertex's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing
by Zacks Equity Research
Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.
Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up
by Zacks Equity Research
Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include: BWXT, EBS, FTNT and HELE
by Zacks Equity Research
Zacks.com featured highlights include: BWXT, EBS, FTNT and HELE
Agenus Stock Up on Licensing Deal With China-Based Firm
by Zacks Equity Research
Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.
4 Momentum Picks Screened on Driehaus Strategy
by Nitish Marwah
Richard Herman Driehaus developed an investment approach based on the buy high and sell higher rule.
Novavax (NVAX) Up More Than 1200% Year to Date: Here's Why
by Zacks Equity Research
Novavax's (NVAX) coronavirus vaccine candidate NVX-CoV2373 enters clinical studies. The company also plans to file a BLA on its influenza vaccine candidate, NanoFlu.
Vaxart Gets New CEO, Focuses on Coronavirus Vaccine Program
by Zacks Equity Research
Vaxart (VXRT) management names Andrei Floroiu as its next chief executive officer with immediate effect. Stock appreciates on this news.
Emergent (EBS) to Manufacture AstraZeneca's Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) inks a deal with AstraZeneca to provide its CDMO services for supporting the manufacturing of the latter's COVID-19 vaccine candidate, AZD1222.
Is Emergent BioSolutions (EBS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Emergent BioSolutions (EBS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is Emergent Biosolutions (EBS) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
Emergent Biosolutions (EBS) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Emergent Biosolutions (EBS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks For June 11th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan
by Zacks Equity Research
Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.
Novavax Clinches $60M Defense Contract for Coronavirus Vaccine
by Zacks Equity Research
Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Emergent Biosolutions (EBS) Up 12.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax Begins Clinical Study for Coronavirus Vaccine
by Zacks.com
Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.
Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine
by Zacks Equity Research
Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.